Intersect ENT (XENT) Tops Q4 EPS by 7c, Beats on Revenues; Offers 1Q18/FY18 Revenue Mid-Point Guidance Below Consensus

Intersect ENT (NASDAQ: XENT) reported Q4 EPS of ($0.11), $0.07 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $29.5 million versus the consensus estimate of $28.71 million.

Outlook

The company continues to forecast full year 2018 revenue of $111 to $116 million, including an estimated 8% contribution from SINUVA product sales, and first quarter 2018 revenue of $23.2 to $23.7 million. The company continues to expect to launch SINUVA commercially in the second quarter of 2018.

The company expects full year 2018 gross margin of approximately 81% to 82% and operating expenses for the year of $113 to $115 million.

GUIDANCE:

Intersect ENT sees FY2018 revenue of $111-116 million, versus the consensus of $114.43 million.

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c